69-Year-Old Female Patient Who Developed Corona Virus Disease 2019 (COVID-19) During Treatment

Back to resources

Dr Sree Munisami shares how he and his team navigated the challenges of treating a high-risk* patient who caught COVID-19 during the course of her acute myeloid leukaemia (AML) therapy.

Prescribing information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

FOOTNOTES

*High-risk AML is defined as therapy-related AML or AML with myelodysplasia-related changes.

ABBREVIATIONS

AML, acute myeloid leukaemia; COVID-19, coronavirus disease 2019.

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2100015 | April 2021